Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 ...
Alto Neuroscience missed the primary endpoint for a study of its ALTO-101 drug for the treatment of cognitive impairment associated with schizophrenia.
Entra en vigor un alto el fuego de 10 días acordado por Israel y Líbano. More News ...
Alto’s ALTO-207 program remains on track to initiate a Phase 2b trial in the first half of 2026. The planned trial will evaluate ALTO-207 as an adjunctive treatment in approximately 178 adults with ...
Trump invita a la Casa Blanca a los líderes de Israel y Líbano para sus primeras conversaciones de alto nivel desde 1983.
Investor's Business Daily on MSN
Top 1% Alto Neuroscience plummets on its shocking schizophrenia miss
Alto Neuroscience deprioritized its lead asset Thursday, a treatment for cognitive impairment due to schizophrenia. The ...
Alto Neuroscience, Inc. ( (ANRO)) has shared an announcement. On April 1, 2026, Alto Neuroscience reported topline Phase 2 proof-of-concept data for ALTO-101 in cognitive impairment associated with ...
Researcher Andrew Dai believes that the artificial intelligence models at big labs have the intelligence of a 3-year-old kid, ...
Moat Index fell 9.55%, lagging as zero energy exposure hurt during the sector’s rally. Fortinet and Palo Alto outperformed, ...
Basically from Odessa to Napanee, all way down Highway 2, we have farmland.” A few hundred metres up the road, Embury gave ...
Artificial intelligence giant Anthropic warned that its vulnerability-scanning AI tool could be used to break operating ...
Despite losing some key pieces from last season, the Brattleboro Unified basketball team will bring a talented roster to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results